Helping patients since 2003

For over 10 years, Valcyte has been prescribed to help prevent cytomegalovirus (CMV) in transplant patients.

What is Valcyte?

Valcyte is an anti-viral medicine that is prescribed to adult transplant patients who have a high chance of developing CMV disease after receiving a heart, kidney, or
kidney-pancreas transplant.*

Valcyte is also prescribed to children (4 months to 16 years) who have a high chance of developing CMV disease after receiving a kidney transplant and to children (1 month to
16 years) who have a high chance of developing CMV
disease after receiving a heart transplant.*

CMV is one of the most serious infections affecting transplant patients. Valcyte works by slowing the ability of CMV to reproduce itself within the body, helping
to prevent CMV disease in transplant patients.

Valcyte is for the following patients who have
a high chance of developing CMV disease:

Adults who
have had a

  • Kidney transplant
  • Heart transplant
  • Kidney-pancreas transplant

Valcyte is available for adults as

Tablets

Children who
have had a

  • Kidney transplant (aged 4 months to 16 years)
  • Heart transplant (aged 1 month to 16 years)

Valcyte is available for children as

Tablets
Oral solution

Not actual size and may not represent exact color.